ABPI reaction to positive results for the Oxford vaccine

Positive news from early trials of the Oxford coronavirus vaccine indicating that the vaccine generates an immune response has been welcomed by the UK pharmaceutical industry. 

In response to the study, published in the Lancet, Chief Executive of the ABPI Richard Torbett said: 

“All over the world, pharmaceutical companies are working in partnership in the search for an effective Covid-19 vaccine and today’s announcement of progress in the UK is extremely positive.

"Developing a vaccine is an incredibly difficult challenge; the fact that there are multiple candidates in development is hopefully a sign that the hard work will ultimately pay off.

"But we must be patient.  Proving that a vaccine is safe and effective is a long process and we could still be many months away.”